Bliv: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinbliv.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Bliv” on the pictured label, suggesting Bliv is the compounder of those drugs when in fact it is not.”

2. 2

   “Accordingly, the representations on your website that Bliv is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

3. 3

   “1) Identifying the entities that produce the compounded products offered on your website;”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

joinbliv.com resolved on 2026-08-09 and redirected to a live GLP-1 prescription funnel titled "Get a GLP-1 Prescription Online | No Calls, No Video | Bliv", running a trust bar that reads "US-based pharmacy · Board certified clinicians · free shipping · no contracts" and claiming "30,000+ happy customers". No pharmacy is named anywhere in the page as fetched — the phrase is the category, "US-based pharmacy", not a name. That is a check of whether the site is up and what it says; it is not a check of anything the letter alleges.

This is the smallest letter in the collection and the small size is the useful part. FDA found one thing and said it twice: a name on a vial in a product photograph is a representation about who made the drug, and here it named the storefront. There is no claim to argue with, no efficacy sentence, no comparison to a brand — just an answer to "who made this" that FDA says was wrong. Which is why the follow-up matters more here than anywhere else. FDA's first request was "Identifying the entities that produce the compounded products offered on your website", and six months later the site still answers with a category rather than a name: "US-based pharmacy". US-based is a fact about geography. It does not tell you whether the filler is a 503A pharmacy dispensing patient by patient or a registered 503B outsourcing facility making batches under federal manufacturing rules, and those are different regimes with different inspection records. A shopper cannot look up "US-based pharmacy". Compare `viviomd`, which received the identical finding and now lists four fillers by name — that is what an answer looks like. Nothing in this letter concerns the drug's quality or contents, and FDA has not closed it out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Bliv failed to respond.